'''Piquindone''' ('''Ro 22-1319''') is an [[atypical antipsychotic]] with a [[tricyclic]] [[chemical structure|structure]] that was developed in the 1980s but was never marketed.<ref name="pmid2890671">{{cite journal |vauthors=Cohen JD, Van Putten T, Marder S, Berger PA, Stahl SM | title = The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia | journal = Journal of Clinical Psychopharmacology | volume = 7 | issue = 5 | pages = 324–9 |date=October 1987 | pmid = 2890671 | doi = 10.1097/00004714-198710000-00006| url = }}</ref><ref name="pmid6116805">{{cite journal  |vauthors=Olson GL, Cheung HC, Morgan KD, etal | title = A dopamine receptor model and its application in the design of a new class of rigid pyrrolo[2,3-g]isoquinoline antipsychotics | journal = Journal of Medicinal Chemistry | volume = 24 | issue = 9 | pages = 1026–34 |date=September 1981 | pmid = 6116805 | doi = 10.1021/jm00141a002| url = }}</ref><ref name="pmid6132425">{{cite journal |vauthors=Davidson AB, Boff E, MacNeil DA, Wenger J, Cook L | title = Pharmacological effects of Ro 22-1319: a new antipsychotic agent | journal = Psychopharmacology | volume = 79 | issue = 1 | pages = 32–9 | year = 1983 | pmid = 6132425 | doi = 10.1007/BF00433013| url = }}</ref> It acts as a [[binding selectivity|selective]] [[D2 receptor|D<sub>2</sub> receptor]] [[receptor antagonist|antagonist]],<ref name="pmid6149457">{{cite journal |vauthors=Nakajima T, Iwata K | title = [3H]Ro 22-1319 (piquindone) binds to the D2 dopaminergic receptor subtype in a sodium-dependent manner | journal = Molecular Pharmacology | volume = 26 | issue = 3 | pages = 430–8 |date=November 1984 | pmid = 6149457 | doi = | url = http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=6149457}}</ref><ref name="pmid2934758">{{cite journal |vauthors=Pugh MT, O'Boyle KM, Molloy AG, Waddington JL | title = Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU24213 | journal = Psychopharmacology | volume = 87 | issue = 3 | pages = 308–12 | year = 1985 | pmid = 2934758 | doi = 10.1007/BF00432713| url = }}</ref><ref name="pmid3529126">{{cite journal |vauthors=Molloy AG, O'Boyle KM, Pugh MT, Waddington JL | title = Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists | journal = Pharmacology, Biochemistry, and Behavior | volume = 25 | issue = 1 | pages = 249–53 |date=July 1986 | pmid = 3529126 | doi = 10.1016/0091-3057(86)90262-5| url = http://linkinghub.elsevier.com/retrieve/pii/0091-3057(86)90262-5}}</ref> though based on its effects profile its selectivity may be considered controversial. Unlike most other D<sub>2</sub> receptor ligands, piquindone displays [[Sodium|Na<sup>2+</sup>]]-dependent [[binding (molecular)|binding]], a property it shares with [[tropapride]], [[zetidoline]], and [[metoclopramide]].<ref name="pmid2715795">{{cite journal |vauthors=Collin S, Vercauteren DP, Vanderveken D, Evrard G, Durant F | title = Structural requirements of Na+-dependent antidopaminergic agents: Tropapride, Piquindone, Zetidoline, and Metoclopramide. Comparison with Na+-independent ligands | journal = Journal of Computer-aided Molecular Design | volume = 3 | issue = 1 | pages = 39–53 |date=March 1989 | pmid = 2715795 | doi = 10.1007/BF01590994| url = }}</ref>
